CClinicalTrials.gg
RecruitingNCT06682429TR-2Updated Sep 9, 2026

Telerehabilitation In The Home After Stroke

An interventional study of Telerehabilitation in Stroke, sponsored by University of California, Los Angeles. Recruiting at 27 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this research study is to evaluate whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone.

Patients with arm weakness due to stroke that happened in the past 90-150 days will be randomized into one of two groups: [1] TR and usual care; [2] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes/day of activities targeting arm function, 6 days a week for 6 weeks.

Read the detailed description

This is a randomized, assessor-blinded study that involves the use of telerehabilitation to deliver additional therapy for persons with stroke. Patients with arm weakness due to stroke that happened in the past 90-150 days will be randomized into one of two groups: [1] TR and usual care; [2] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes/day of activities targeting arm function, 6 days a week 6-8 weeks. The hypothesis of this study is patients receiving TR in addition to their usual care will have significantly greater recovery of arm function compared to patients receiving usual care alone.

Study participation will last approximately 8 months and includes 4 in-person visits. At these visits, patients will undergo a variety of assessments including tests of arm function and a single MRI scan of the brain. Patients undergoing TR will receive arm motor training, which consists of 36 sessions of assigned exercises, games, and stroke education; these total 70 minutes in length and occur 6 days a week for 6 weeks; TR subjects will also continue usual care. Patients in the usual care group only will not engage in TR but will instead continue all of the therapies recommended by their medical team. At the end of the study, participants in the usual care group will be offered TR.

02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • stroke
  • rehabilitation
  • telehealth
03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's planned enrollment of 202 is above the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age 18-80 years at the time of randomization
  2. The index stroke was radiologically verified, due to ischemia or intracerebral hemorrhage (ICH), and had time of onset 120±30 days prior to randomization
  3. The stroke caused upper extremity deficits as defined by Action Research Arm Test score 18-44 (out of 57) at Baseline Visit 1
  4. Box \& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit 1
  5. Able to successfully perform all 3 rehabilitation exercise test examples (simple commands) at Baseline Visit 1
  6. Informed consent and behavioral contract signed by the subject (i.e., no surrogate consent)

Exclusion criteria

Exclusion Criteria:

  1. A major, active, coexistent neurological, psychiatric, or medical disease that reduces the likelihood that a subject will be able to comply with all study procedures
  2. Unable or unwilling to perform study procedures/therapy, or expectation of noncompliance with study procedures/therapy, or expectation that subject cannot participate in all study visits
  3. A diagnosis (apart from the index stroke) that substantially affects paretic arm function
  4. Severe depression, defined as Geriatric Depression Scale Score >10/15 at Baseline Visit 1
  5. Significant cognitive impairment, defined as Montreal Cognitive Assessment score \<22 [a lower score is permitted if due to aphasia and allowed by the site PI]
  6. Deficits in communication that interfere with reasonable study participation
  7. Severe UE spasticity, defined as presence of contracture or modified Ashworth Scale score=4 in either biceps or pectoralis
  8. Modified Rankin Scale score was >2 prior to the index stroke
  9. A new symptomatic stroke has occurred since the index stroke, or a separate stroke occurred within 30 days prior to the index stroke
  10. Lacking visual acuity, with or without corrective lens, of 20/50 or better in at least one eye
  11. Life expectancy \< 9 months
  12. Pregnant; women of child-bearing potential must have a negative pregnancy test
  13. Botulinum toxin to the paretic arm: received in the prior 3 months OR expected by the 8-Month Visit
  14. Concurrent enrollment in another therapy-based investigational study where the duration of the investigational therapy's activity is likely to occur during the subject's participation in the study
  15. Subject lacks sufficient English or Spanish to comply with study procedures and TR instructions
  16. Expectation that subject will not have a single domicile address during the 6 weeks of therapy that is within 1.5-hr drive of the central study site [this can be waived at the discretion of the site PI]
  17. Contraindication to MRI
  18. On isolation precautions, e.g., due to active COVID-19
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
202 participants (estimated)

Study arms

  • No intervention
    Usual Care

    Participants in the usual care group will receive no TR, but will continue with the recommendations made by their care team. All participants in this group will be offered TR at the end of the study.

  • Experimental
    Telerehabilitation + Usual Care

    Patients will receive 36 telerehabilitation sessions targeting arm motor function in addition to their usual care. TR consists of 70 minutes/day of activities targeting arm function, 6 days/week for 6 weeks. Half of these sessions are supervised by a licensed therapist, and the other half are done independently.

    Device: Telerehabilitation

Interventions

  • DeviceTelerehabilitation

    The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.

06

What researchers measure

Primary outcomes

  1. Change in Action Research Arm Test (ARAT) Score from Baseline to 2 Months

    The ARAT scale measures arm function using a scale that runs from 0 to 57 points, with higher numbers reflecting better arm function.

    Time frame: 2 months

Secondary outcomes

  1. Change in modified Rankin Scale (mRS) Score from Baseline to 2 Months

    The mRS scale measures global function using a scale that runs from 0 to 6 points, with lower numbers reflecting better global function.

    Time frame: 2 months

07

Study locations

23 of 27 sites recruiting
  • Rancho Los Amigos Research Institute
    Downey, California 90242, United States
    • Jason Garcia · Contact · jasong@ranchoresearch.org · (562)385-6939
    • Charles Liu, MD · Principal investigator
    • Shailesh Kantak, PhD · Sub investigator
    • Susan Shaw, MD · Sub investigator
    Recruiting
  • University of California, Irvine
    Irvine, California 92868, United States
    • Lucy Dodakian, OT · Contact · ldodak@hs.uci.edu · (949)824-8748
    • An Do, MD · Principal investigator
    Recruiting
  • Keck Medical Center of USC
    Los Angeles, California 90033, United States
    • Stuti Chakraborty · Contact · stuticha@usc.edu · (626)642-8213
    • Sook-Lei Liew, PhD · Principal investigator
    Recruiting
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
    • Ryan McCarville · Contact · tr2trial@mednet.ucla.edu · (424)522-7874
    • Steven C Cramer, MD, FAAN, FAHA · Principal investigator
    Recruiting
  • Casa Colina Hospital and Centers for Healthcare
    Pomona, California 91767, United States
    Recruiting
  • Hillcrest Medical Center at UC San Diego Health
    San Diego, California 92103, United States
    Recruiting
  • Medstar Health Research Institute
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Brooks Rehabilitation Hospital
    Jacksonville, Florida 32216, United States
    • Taisiya Matev · Contact · taisiya.matev@brooksrehab.org · (904)345-8973
    • Lauren Shapiro, MD · Principal investigator
    • Mark Bowden, PT, PhD · Sub investigator
    Recruiting
  • Jackson Memorial Hospital Christine E. Lynn Rehabilitation Center
    Miami, Florida 33136, United States
    • Dinorah Rodriguez, RN · Contact · drodriguez5@med.miami.edu · (305)243-2797
    • Sony Isaac, MD · Principal investigator
    • Leslie Morse, DO · Sub investigator
    Not yet recruiting
  • Emory Rehabilitation Hospital
    Atlanta, Georgia 30322, United States
    • Susan Murphy · Contact · smurph7@emory.edu · (404)712-1928
    • Michael Borich, PhD, PT · Principal investigator
    Recruiting
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    • Sasha Moores · Contact · smoores@kumc.edu · (913)588-2697
    • Sandra Billinger, PhD, PT · Principal investigator
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • Spaulding Rehabilitation Hospital
    Charlestown, Massachusetts 02129, United States
    Recruiting
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
    Recruiting
  • University of Michigan University Hospital
    Ann Arbor, Michigan 48108, United States
    • Danny Shin · Contact · ddshin@umich.edu · (734)615-3904
    • Chandramouli Krishnan, PhD · Principal investigator
    • Edward Claflin, MD · Sub investigator
    Recruiting
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
    • Karolina Roszkowski · Contact · karolina.roszkowski@mountsinai.org · 929-637-5818
    • David Putrino, PhD · Principal investigator
    • Christopher Kellner, MD · Sub investigator
    • Jenna Tosto, PT · Sub investigator
    Recruiting
  • NYP Columbia University Medical Center
    New York, New York 10032, United States
    Recruiting
  • University of North Carolina Medical Center
    Chapel Hill, North Carolina 27514, United States
    • Jessica Cassidy · Contact · jcassidy@med.unc.edu · (919)843-5774
    • Jessica Cassidy, PhD, PT · Principal investigator
    Recruiting
  • Duke University Hospital
    Durham, North Carolina 27710, United States
    Recruiting
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
    • Colin Drury · Contact · drurycd@ucmail.uc.edu · (513)558-7656
    • Oluwole Awosika, MD · Principal investigator
    Recruiting
  • MetroHealth Old Brooklyn Health Center
    Cleveland, Ohio 44109, United States
    • Krissy Hansen, PT · Contact · khansen1@metrohealth.org · (216)957-3584
    • David Cunningham, PhD · Principal investigator
    Not yet recruiting
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
    • Heidi Poppendeck · Contact · poppenh@ccf.org · (216)704-3675
    • Christina Xia, MD · Principal investigator
    Not yet recruiting
  • Jefferson Moss Rehabilitation Research Institute
    Elkins Park, Pennsylvania 19027, United States
    • Paria Arfa-Fatollahkhani · Contact · tr2trial@mednet.ucla.edu · (215)663-6400
    • Dylan Edwards, PhD · Principal investigator
    • Alberto Esquenazi, MD · Sub investigator
    Recruiting
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    • Terry Roddey · Contact · roddeyt@musc.edu · (843)725-8045
    • Parneet Grewal, MD · Principal investigator
    • Michelle Woodbury, PhD · Sub investigator
    Recruiting
  • The Institute for Rehabilitation and Research (TIRR) Memorial Hermann
    Houston, Texas 77030, United States
    Not yet recruiting
  • UT Houston/Memorial Hermann Hospital TMC
    Houston, Texas 77030, United States
    Recruiting
  • University of Utah Health
    Salt Lake City, Utah 84132, United States
    • Amit Sethi, MD · Contact · amit.sethi@utah.edu · (801)585-9292
    • Amit Sethi, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Non-PHI data will be shared with appropriate parties after the study is completed and published.

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06682429
Lead sponsor
University of California, Los Angeles
Collaborators
Moss Rehabilitation Research Institute, National Institute of Neurological Disorders and Stroke (NINDS)
Responsible party
Steven C. Cramer, MD, FAAN, FAHA, FASNR (Professor, University of California, Los Angeles) — Principal investigator
First posted
Nov 12, 2024
Start date
Aug 22, 2025
Primary completion
Jun 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Sep 9, 2026

Study contacts

Steven Cramer, MD
Contact
tr2trial@mednet.ucla.edu
(424)522-7874
Steven Cramer, MD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion